The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
Nicholas C. Richardson, Yvette L. Kasamon, Richard Pazdur, Nicole Gormley
Topics & Concepts
IdelalisibMedicineRituximabChronic lymphocytic leukemiaInternal medicineOncologyLymphomaClinical endpointClinical trialImmunologyLeukemiaIbrutinibChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentViral-associated cancers and disorders